Shares of YD Bio Limited (NASDAQ:YDES – Get Free Report) rose 7.9% on Monday . The company traded as high as $7.50 and last traded at $7.8770. Approximately 759 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 37,850 shares. The stock had previously closed at $7.30.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the company. Weiss Ratings reissued a “sell (d+)” rating on shares of YD Bio in a report on Monday, December 29th. Wall Street Zen raised YD Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, YD Bio presently has a consensus rating of “Sell”.
Check Out Our Latest Report on YD Bio
YD Bio Stock Performance
Institutional Inflows and Outflows
An institutional investor recently raised its position in YD Bio stock. Geode Capital Management LLC increased its position in shares of YD Bio Limited (NASDAQ:YDES – Free Report) by 10.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 58,363 shares of the biotechnology company’s stock after acquiring an additional 5,292 shares during the period. Geode Capital Management LLC owned about 0.08% of YD Bio worth $711,000 at the end of the most recent reporting period.
YD Bio Company Profile
YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.
See Also
Receive News & Ratings for YD Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for YD Bio and related companies with MarketBeat.com's FREE daily email newsletter.
